Industry leaders say demand for these higher-value tests aimed at early disease detection, personalised treatment and long-term health management has been expanding far faster than routine pathology
Despite GST relief making small cars cheaper, India's used-car market continues to favour SUVs, which are seeing faster inventory turnover and stronger residual values, industry executives say
The Mumbai-based pharma company has commissioned a ₹165-crore formulations plant at Ambernath to support contract manufacturing and strengthen its presence in regulated global markets
Chairman Anand Mahindra says artificial intelligence, skills and education reforms will reshape work, talent flows and growth, as the Group sharpens its technology-focused strategy
Ducati India says the 40 per cent GST on large-capacity bikes has added pressure on demand and is counting on the proposed India-EU FTA to ease import costs from 2026
Hyundai Motor India has launched Prime HB and Prime SD taxi models with petrol and CNG options, aiming to diversify volumes as domestic competition heats up and rankings tighten
Lupin has signed an exclusive licensing, supply and distribution deal with China's Gan & Lee for Bofanglutide, a fortnightly GLP-1 injectable for diabetes and weight management in India
Diagnostic chains are expanding laboratories, integrated centres and collection networks as demand grows for preventive, genomics-led and precision testing across India
Triumph will revise ex-showroom prices across its range from January 1, while Renault India will raise prices by up to 2 per cent, urging buyers to lock in current rates
A string of CDSCO approvals and reviews is accelerating India's move to immunotherapies, ADCs and targeted drugs, widening options in major cancers and boosting competition
India's diagnostics sector is seeing a strong shift towards preventive and precision-led testing in 2025, driven by rising demand for proactive health checks and faster genomic diagnostics
Tata Passenger Electric Mobility plans five new EV models by FY30 and Rs 16,000-18,000 crore capex on products, technology and charging infrastructure as Tata EV sales cross 250,000 units
HN Reliance Foundation Hospital has launched a tele-robotic surgery programme, allowing Mumbai surgeons to remotely perform, guide robotic procedures at a Jamnagar partner centre using Jio's network
Cipla has launched Afrezza, an inhaled rapid-acting insulin for adults with diabetes, after CDSCO approval, and plans an awareness drive on insulin adherence
As GLP-1 competition heats up, Emcure is pricing semaglutide brand Poviztra at ₹8,790 a month and targeting demand beyond metros with deeper distribution in smaller cities
Cipla will exclusively market five Pfizer brands in India, adding ₹400-430 crore of established acute therapies to its portfolio without manufacturing risk
